MyFinsight
Home
Blog
About
Contact
Download
Download image
Income and revenues
$52,149K
U.s. federal
statutory tax rate
$6,681K
Gains on acquisitions
$21,224K
Other income, net
$12,145K
Change in fair value of
derivatives related to...
$93K
Nondeductible executive
compensation
$735K
Other permanent
differences
$163K
Foreign tax effects
$103K
Net cash and
restricted cash acquired in...
$46,384K
Net cash and
restricted cash acquired in...
$15,263K
Net income (loss)
$31,712K
Sale of equity
securities
$6,999K
Receipt from short-term
loan repayment by...
$5,877K
Net cash and
restricted cash acquired in...
$4,464K
Net cash acquired in
acquisition-Turnstone Biologics Corp
$3,850K
Receipts under rpas,
aaas, and cppas
$3,300K
Stock-based compensation
expense
$9,273K
Prepaid expenses and
other assets
-$3,839K
Amortization of intangible
assets
$2,961K
Accretion of long-term
debt discount and...
$1,385K
Common stock
contribution to 401
$141K
Income tax expense
(benefit)
$103K
Non-cash lease expense
-$64K
Depreciation
$11K
Canceled cashflow
$53,899K
Canceled cashflow
$7,579K
Net cash provided by
(used in) investing...
$50,886K
Net cash provided by
(used in) operating...
$2,871K
Canceled cashflow
$35,251K
Canceled cashflow
$46,618K
Other general and
administrative expenses
$29,427K
Interest expense
$13,031K
Business development and
deal related costs
$6,654K
Amortization of intangible
assets
$2,961K
Research and development
expenses
$1,712K
Income tax (expense)
benefit
$103K
Depreciation of property and
equipment
$11K
Bargain purchase gain
$4,457K
Changes in valuation
allowances
-$2,538K
Stock based
compensation
-$584K
Net increase
(decrease) in cash, cash...
$27,294K
Canceled cashflow
$26,463K
Payment for bioinvent
contract-based intangible...
$20,725K
Payments of
consideration under rpas,...
$8,000K
Payment to issue
short-term loan to xeno
$5,877K
Payment of contingent
consideration related to...
$550K
Purchase of equity
securities
$99K
Proceeds from exercise of
options and other...
$5,046K
Proceeds from issuance of
preferred stock
$4,019K
Proceeds from issuance of
common stock
$323K
Gains on acquisitions
$21,224K
Accounts payable and
accrued liabilities
-$10,597K
Adjustment for income from
eir method...
-$5,925K
Gain on sale of equity
securities
$3,663K
Trade and other
receivables, net
$2,426K
Unearned revenue
recognized under...
-$1,310K
Operating lease
liabilities
-$876K
Cvr liability
working capital...
$394K
Change in fair value of
derivatives
$93K
Change in fair value of
equity securities
$90K
Change in fair value of
available-for-sale debt securities...
-$20K
Net cash used in
financing activities
-$26,463K
Canceled cashflow
$9,388K
Repurchases of common stock
$16,043K
Principal payments - debt
$10,598K
Payment of preferred
stock dividends
$5,472K
Taxes paid related to
net share...
$2,986K
Payments of preferred and
common stock issuance...
$672K
Debt issuance costs
and loan fees paid in...
$80K
Back
Back
Cash Flow
source: myfinsight.com
XOMA Royalty Corp (XOMAP)
XOMA Royalty Corp (XOMAP)